These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2464143)

  • 1. Alpha-fetoprotein, carcinoembryonic antigen and various biochemical tests in patients with tumorous and inflammatory liver diseases.
    Weber P; Weberová D; Martínek K
    Neoplasma; 1988; 35(5):605-13. PubMed ID: 2464143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoembryonic antigen (CEA) in patients with malignant and non-malignant diseases.
    Alsabti EA; Kamel A
    Neoplasma; 1979; 26(5):603-9. PubMed ID: 230422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Subject diagnostic value of detecting a1pha-fetoprotein variants with a new microspincolumn method in hepatocellular carcinoma].
    Xu AF; Wang MC; Sui DM; Yuan YH; Chen G; Lou GQ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):67-9. PubMed ID: 17429541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative study of the plasma levels of alpha-1 fetoprotein and carcinoembryonic antigen in chronic liver diseases and malignant neoplasias (author's transl)].
    Del Vecchio-Blanco C; Caporaso N; Balzano A; Grande R
    Quad Sclavo Diagn; 1977 Sep; 13(3):288-97. PubMed ID: 77537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor markers in focal and diffuse liver diseases].
    Kasatkin IuN; Ametov AS; Mit'kov VV; Sevast'ianov SI; Zarudin VV
    Med Radiol (Mosk); 1984 Apr; 29(4):39-43. PubMed ID: 6201693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.
    Wu W; Yao DF; Yuan YM; Fan JW; Lu XF; Li XH; Qiu LW; Zong L; Wu XH
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):538-44. PubMed ID: 17085339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum concentrations of tissue polypeptide antigen and alpha 1-fetoprotein in patients with primary liver cancer, liver metastasis and liver cirrhosis].
    Polterauer P; Legenstein E; Müller M
    Wien Klin Wochenschr; 1985 Apr; 97(9):417-20. PubMed ID: 2408389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
    Lamerz R; Runge M; Stieber P; Meissner E
    Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of tissue polypeptide specific antigen as a marker in liver diseases.
    Cetin T; Oğuz A; Algan P; Yildirim IS
    Turk J Gastroenterol; 2003 Sep; 14(3):177-80. PubMed ID: 14655061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
    Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
    Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential tumor markers and hepatitis markers profile in liver tumors.
    Khalifa A; Mady EA; Abadeer N; Kamal A
    Anticancer Res; 1999; 19(4A):2495-500. PubMed ID: 10470181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential diagnosis of liver diseases using serum biomarkers.
    Cujic D; Golubovic S; Bojic-Trbojevic Z; Ilic N; Baricevic I; Nedic O
    J BUON; 2010; 15(1):141-6. PubMed ID: 20414942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Severely increased alpha fetoprotein and associated diseases].
    Ganz M; Joller-Jemelka HI; Grob PJ
    Schweiz Med Wochenschr; 1979 Sep; 109(36):1314-22. PubMed ID: 92051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
    Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
    Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of alpha-fetoprotein-L3 using agglutinin-coupled spin column to be used in diagnosis of hepatocellular carcinoma].
    Sun GZ; Zhao XY; Li JH; Zhao GQ; Wang SX; Kong SL
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1986-8. PubMed ID: 19062741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminant analysis in the clinical and biochemical diagnosis of primary liver cancer.
    Farinati F; Varnier M; Piccoli A; Caldironi MW; Zotti S; Plebani M; Di Mario F; Naccarato R
    J Med; 1986; 17(5-6):347-55. PubMed ID: 2438364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The occurrence and significance of the presence of alpha fetoprotein (AFP) and Australia antigen (HBsAg) in the serum of 392 patients with chronic disease and primary malignant neoplasms of the liver].
    Stajić M; Milosavljević J
    Acta Med Iugosl; 1978; 32(3):243-51. PubMed ID: 80098
    [No Abstract]   [Full Text] [Related]  

  • 19. Thyroxine-binding globulin as a marker of liver tumors.
    Terui S; Moriya Y; Yamamoto H; Koyama Y
    Cancer Detect Prev; 1987; 10(5-6):371-8. PubMed ID: 2436781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of several tumor markers in the diagnosis of primary hepatic cancer].
    Shi X; Zhou Y; Xia L
    Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):437-9. PubMed ID: 10920938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.